Fabhalta
(Danicopan)Phase 2Small molecule
AstraZenecaDanicopan is used to prevent blood cell destruction in patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), helping protect red blood cells from being attacked by the immune system.[1] Fabhalta is currently being investigated across 8 indications[3], with its most advanced program in Phase 2.[1]
Fabhalta is one of 182 small molecule programs targeting Glomerulonephritis. It is currently in Phase 2.
8
Indications
26
Total Trials
4
Active Trials
181
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Fabhalta
AstraZenecaPhase 2
Biaxin
AbbViePreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Blood Taken
HHospices Civils de Lyon
Preclinical
Standard Preparation
LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Preclinical
Moderna COVID-19 Vaccine
ModernaPreclinical
COVID-19 Vaccines
UUniversity of British Columbia
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Paroxysmal Nocturnal Hemoglobinuria4 trials
ART3 trials
Interaction2 trials
Hemolysis1 trial
15 more indications
Function1 trial
IC-MPGN1 trial
Drug Interactions1 trial
COVID-191 trial
ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04988035·201 enrolled
Age-Related Macular Degeneration1 trial
Safety and Efficacy1 trial
Treatment1 trial
C3 Glomerulopathy (C3G)1 trial
Regulatory
FDA Approval Timeline[4]
Mar 29, 2024
VOYDEYA
NDA NDA218037
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Danicopan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Complement Factor D Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company